Physician profile
Eric Zephirin
NPI 1700278322
$615.12
in general payments reported to CMS, 2019-2025
11 companies · $20.36 in 2025
The $20.36 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $69.43 · 2021: $67.25 · 2022: $152 · 2023: $46.06 · 2024: $131 · 2025: $20.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $196.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $171.99 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Nevro Corp. | $120.82 | 2022 | |
| Medela LLC | $64.37 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $62.50 | 2019 | |
| Embody, INC. | $53.24 | 2021 | |
| Innovation Technologies INC | $48.75 | 2024 | Irrisept |
| Kowa Pharmaceuticals America, INC. | $27.64 | 2023 | Seglentis |
| Paratek Pharmaceuticals, INC. | $20.36 | 2025 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.56 | 2022 | |
| Kci USA, INC. | $14.01 | 2021 | |
| Bioventus LLC | $13.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Zephirin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.